Analysis of use of different rFSHs during IVF/ICSI-assisted conception in elderly population and effect of double trigger on clinical outcomes

References

• Hu L, Zhang S, Quan S, et al. Efficacy and safety of recombinant human follicle-stimulating hormone in patients undergoing in vitro fertilization–embryo transfer. Aging. 2020;12(6):1–9. doi:10.18632/aging.102919.
   PubMedGoogle Scholar
• Kawwass JF, Badell ML. Maternal and fetal risk associated with assisted reproductive technology. Obstet Gynecol. 2018;132(3):763–772. doi:10.1097/AOG.0000000000002786.
   PubMed Web of Science ®Google Scholar
• Crawford GE, Ledger WL. In vitro fertilisation/intracytoplasmic sperm injection beyond 2020. BJOG. 2019;126(2):237–243. doi:10.1111/1471-0528.15526.
   PubMed Web of Science ®Google Scholar
• Huang H, Itaya Y, Samejima K, et al. Usefulness of random-start progestin-primed ovarian stimulation for fertility preservation. J Ovarian Res. 2022;15(1):2. doi:10.1186/s13048-021-00935-5.
   PubMed Web of Science ®Google Scholar
• Kedem A, Avraham S, Yerushalmi G, et al. P-396 modified flare/GnRH antagonist protocol versus GnRH antagonist protocol in oocyte cryopreservation cycles. Hum Reprod. 2023;38. doi:10.1093/humrep/dead093.747.
   Google Scholar
• Fancsovits P, Lehner A, Kaszas Z, et al. Intracytoplasmic sperm injection does not improve the outcome of IVF treatments in patients with advanced maternal age or low oocyte number: a randomized controlled trial. J Gynecol Obstet Hum Reprod. 2023;52(8):102625. doi:10.1016/j.jogoh.2023.102625.
   PubMed Web of Science ®Google Scholar
• Dansuk R, Gonenc AI, Sudolmus S, et al. Effect of GnRH antagonists on clinical pregnancy rates in ovulation induction protocols with gonadotropins and intrauterine insemination. Singapore Med J. 2015;56(6):353–356. doi:10.11622/smedj.2014192.
   PubMed Web of Science ®Google Scholar
• Albu D, Albu A. The ratio of exogenous luteinizing hormone to follicle stimulating hormone administered for controlled ovarian stimulation is associated with oocytes’ number and competence. Biosci Rep. 2020;40(1):BSR20190811. doi:10.1042/BSR20190811.
   PubMedGoogle Scholar
• Zhu X, Ye H, Fu Y. The utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments. Medicine. 2016;95(28):e4193. doi:10.1097/MD.0000000000004193.
   PubMed Web of Science ®Google Scholar
• Tian L, Tan J, Zou Y, et al. Mild starting dosage ovarian stimulation combined with a modified prolonged GnRH-a protocol improved IVF/ICSI outcomes in normal ovarian responders. Arch Med Sci. 2019;15(5):1294–1300. doi:10.5114/aoms.2019.85145.
   PubMed Web of Science ®Google Scholar
• Wu Y, Tu M, Huang Y, et al. Association of metformin with pregnancy outcomes in women with polycystic ovarian syndrome undergoing in vitro fertilization: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(8):e2011995. doi:10.1001/jamanetworkopen.2020.11995.
   PubMed Web of Science ®Google Scholar
• Siristatidis C, Salamalekis G, Dafopoulos K, et al. Mild versus conventional ovarian stimulation for poor responders undergoing IVF/ICSI. In Vivo. 2017;31(2):231–237. doi:10.21873/invivo.11050.
   PubMed Web of Science ®Google Scholar
• Mills G, Dahan MH. Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin. Arch Gynecol Obstet. 2022;306(5):1731–1737. doi:10.1007/s00404-022-06717-8.
   PubMed Web of Science ®Google Scholar
• Pereira N, Elias RT, Neri QV, et al. Adjuvant gonadotrophin-releasing hormone agonist trigger with human chorionic gonadotrophin to enhance ooplasmic maturity. Reprod Biomed Online. 2016;33(5):568–574. doi:10.1016/j.rbmo.2016.08.009.
   PubMed Web of Science ®Google Scholar
• Lin M, Wu FS, Hwu YM, et al. Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve. Reprod Biol Endocrinol. 2019;17(1):7. doi:10.1186/s12958-018-0451-x.
   PubMedGoogle Scholar
• Kaye L, Griffin D, Thorne J, et al. Independent serum markers of corpora lutea function after gonadotropin-releasing hormone agonist trigger and adjuvant low dose human chorionic gonadotropin in in vitro fertilization. Fertil Steril. 2019;112(3):534–544. doi:10.1016/j.fertnstert.2019.04.034.
   PubMed Web of Science ®Google Scholar
• Kawamura K, Ishizuka B, Hsueh A. Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve. Reprod Biomed Online. 2020;40(2):245–253. doi:10.1016/j.rbmo.2019.09.007.
   PubMed Web of Science ®Google Scholar
• Yong PY, Brett S, Baird DT, et al. A prospective randomized clinical trial comparing 150 IU and 225 IU of recombinant follicle-stimulating hormone (Gonal-F*) in a fixed-dose regimen for controlled ovarian stimulation in in vitro fertilization treatment. Fertil Steril. 2003;79(2):308–315. doi:10.1016/s0015-0282(02)04583-1.
   PubMed Web of Science ®Google Scholar
• Moon SY, Choi YS, Ku SY, et al. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology. J Obstet Gynaecol Res. 2007;33(3):305–315. doi:10.1111/j.1447-0756.2007.00529.x.
   PubMed Web of Science ®Google Scholar
• Drakopoulos P, Blockeel C, Stoop D, et al. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? Hum Reprod. 2016;31(2):370–376.
   PubMed Web of Science ®Google Scholar
• Li R, Lu L, Hao G, et al. Abdominal ultrasound-guided embryo transfer improves clinical pregnancy rates after in vitro fertilization: experiences from 330 clinical investigations. J Assist Reprod Genet. 2005;22(1):3–8. doi:10.1007/s10815-005-0813-0.
   PubMed Web of Science ®Google Scholar
• Samura O, Nakaoka Y, Miharu N. Sperm and oocyte chromosomal abnormalities. Biomolecules. 2023;13(6):1010. doi:10.3390/biom13061010.
   PubMed Web of Science ®Google Scholar
• Belva F, Bonduelle M, Buysse A, et al. Chromosomal abnormalities after ICSI in relation to semen parameters: results in 1114 fetuses and 1391 neonates from a single center. Hum Reprod. 2020;35(9):2149–2162. doi:10.1093/humrep/deaa162.
   PubMed Web of Science ®Google Scholar
• Sunkara SK, Rittenberg V, Raine-Fenning N, et al. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011;26(7):1768–1774. doi:10.1093/humrep/der106.
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Kuroda K, Sugiyama R. Clinical strategies for ART treatment of infertile women with advanced maternal age. Reprod Med Biol. 2018;18(1):27–33. doi:10.1002/rmb2.12240.
   PubMed Web of Science ®Google Scholar
• Stimulation TEGG, Bosch E, Broer S, et al. ESHRE guideline: ovarian stimulation for IVF/ICSI†. Hum Reprod Open. 2020;2020(2):hoaa009.
   PubMedGoogle Scholar
• Stamatiades GA, Carroll RS, Kaiser UB. GnRH—a key regulator of FSH. Endocrinology. 2019;160(1):57–67. doi:10.1210/en.2018-00889.
   PubMed Web of Science ®Google Scholar
• Var T, Tonguc EA, Doğanay M, et al. A comparison of the effects of three different luteal phase support protocols on in vitro fertilization outcomes: a randomized clinical trial. Fertil Steril. 2011;95(3):985–989. doi:10.1016/j.fertnstert.2010.06.057.
   PubMed Web of Science ®Google Scholar
• Dosouto C, Haahr T, Humaidan P. Gonadotropin-releasing hormone agonist (GnRHa) trigger – state of the art. Reprod Biol. 2017;17(1):1–8. doi:10.1016/j.repbio.2017.01.004.
   PubMed Web of Science ®Google Scholar
• Chen C, Tzeng C, Wang PH, et al. Dual triggering with GnRH agonist plus hCG versus triggering with hCG alone for IVF/ICSI outcome in GnRH antagonist cycles: a systematic review and meta-analysis. Arch Gynecol Obstet. 2018;298(1):17–26. doi:10.1007/s00404-018-4751-3.
   PubMed Web of Science ®Google Scholar
• Coelho NM, Ludwin A, Borrell A, et al. Counting ovarian antral follicles by ultrasound: a practical guide. Ultrasound Obstet Gynecol. 2018;51(1):10–20. doi:10.1002/uog.18945.
   PubMed Web of Science ®Google Scholar
• Schachter M, Friedler S, Ron-El R, et al. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril. 2008;90(4):1087–1093. doi:10.1016/j.fertnstert.2007.07.1316.
   PubMed Web of Science ®Google Scholar
• Gullo G, Scaglione M, Laganà AS, et al. Assisted reproductive techniques and risk of congenital heart diseases in children: a systematic review and meta-analysis. Reprod Sci. 2023;30(10):2896–2906. doi:10.1007/s43032-023-01252-6.
   PubMed Web of Science ®Google Scholar
• Gullo G, Scaglione M, Cucinella G, et al. Impact of assisted reproduction techniques on the neuro-psycho-motor outcome of newborns: a critical appraisal. J Obstet Gynaecol. 2022;42(7):2583–2587. doi:10.1080/01443615.2022.2109953.
   PubMedGoogle Scholar
• Medenica S, Zivanovic D, Batkoska L, et al. The future is coming: artificial intelligence in the treatment of infertility could improve assisted reproduction outcomes—the value of regulatory frameworks. Diagnostics. 2022;12(12):2979. doi:10.3390/diagnostics12122979.
   Web of Science ®Google Scholar